Bei Akademie registrieren
EYPT, US30233G2093

EyePoint stock: Stifel cuts target after trial setbacks

Published on 11/13/2026 at 22:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
EyePoint stock faces a lower Stifel target after wet AMD trial setbacks. The analyst keeps a Buy rating as DME becomes the key program.

Stifel Lowers Target After Trial Setbacks

  • Stifel cut its EyePoint price target after the LUGANO and LUCIA wet AMD trials missed their primary endpoints.
  • The company is prioritizing DURAVYU for diabetic macular edema after reducing its workforce by about 53%.
  • Phase 3 COMO and CAPRI data are expected in early fourth-quarter 2027.
EYPT, US30233G2093, Illustration mit AI erstellt.
EYPT, US30233G2093, Illustration mit AI erstellt.

Stifel lowered its price target for EyePoint Inc. from 5.00 to 5.00? No.

Disclaimer...
en | US30233G2093 | EYPT | boerse | 70506812 | bgmi